This Dashboard takes a closer look at the trending use of liquid biopsies and the study of circulating biomarkers like ctDNA, CTCs, and cfDNA.
Circulating Biomarker Trends: 2005 – 2015
In recent years there has been a surge in research interest in using less invasive circulating biomarkers like circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and cell-free DNA (cfDNA) for improved diagnostics in diseases like cancer and reproductive health screening.
Current sample acquisition for both of these fields are invasive and can be painful or introduce risks to the patient. The presence of circulating biomarkers like ctDNA, CTCs, and cfDNA and improvements in methods to isolate them from patients hold promise to development more effective diagnostics, prognostics, and monitoring methods for a range of clinical settings.
This Dashboard takes a closer look at the trending study of liquid biopsies and/or circulating biomarkers like ctDNA, CTCs, and cfDNA.
Inside this Dashboard
This Market Trends Dashboard summarizes the trending study of circulating biomarkers. Inside it you’ll find:
- The relative frequency of study of various circulating biomarkers including ctDNA, CTCs, and cfDNA measured in total volume of publication mentions
- The total volume of mentions over time
- The growth rate trending for each of the biomarkers
- Regional segmentation: total mention volume and growth rates broken down for reach region, country, and even by state in the US